Decensi A - Search Results

1

Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study.

Decensi A, Bonanni B, Rotmensz N, Robertson C, Guerrieri-Gonzaga A, Mora S, Diani S, Cazzaniga M, Costa A. Decensi A, et al. Eur J Cancer. 2000 Sep;36 Suppl 4:S50-1. doi: 10.1016/s0959-8049(00)00224-0. Eur J Cancer. 2000. PMID: 11056317 Clinical Trial. No abstract available.

2

Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).

Decensi A, Guarneri D, Paoletti MC, Lalanne JM, Merlo F, Boccardo F. Decensi A, et al. Eur J Cancer. 1991;27(9):1100-4. doi: 10.1016/0277-5379(91)90301-s. Eur J Cancer. 1991. PMID: 1835617 Clinical Trial.

3

The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.

Torrisi R, Pensa F, Fontana V, Costa A, Decensi A. Torrisi R, et al. Among authors: decensi a. Eur J Cancer. 1995;31A(3):420-1. doi: 10.1016/0959-8049(94)00524-9. Eur J Cancer. 1995. PMID: 7786612 No abstract available.

4

Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.

Torrisi R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A. Torrisi R, et al. Among authors: decensi a. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):507-10. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8000302

5

Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.

Decensi A, Formelli F, Torrisi R, Costa A. Decensi A, et al. J Cell Biochem Suppl. 1993;17G:226-33. doi: 10.1002/jcb.240531142. J Cell Biochem Suppl. 1993. PMID: 8007703 Clinical Trial.

6

Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.

Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Costa A, et al. Among authors: decensi a. Cancer Res. 1994 Apr 1;54(7 Suppl):2032s-2037s. Cancer Res. 1994. PMID: 8137334 Review.

7

Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.

Decensi A, Torrisi R, Polizzi A, Gesi R, Brezzo V, Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A. Decensi A, et al. J Natl Cancer Inst. 1994 Jan 19;86(2):105-10. doi: 10.1093/jnci/86.2.105. J Natl Cancer Inst. 1994. PMID: 8271292 Clinical Trial.

8

The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.

Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A. Torrisi R, et al. Among authors: decensi a. Cancer Res. 1993 Oct 15;53(20):4769-71. Cancer Res. 1993. PMID: 8402658 Clinical Trial.

9

Retinoids and tamoxifen in breast cancer chemoprevention.

Costa A, Sacchini V, Decensi A. Costa A, et al. Among authors: decensi a. Int J Clin Lab Res. 1993;23(2):53-5. doi: 10.1007/BF02592283. Int J Clin Lab Res. 1993. PMID: 8518414

10

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.

Costa A, De Palo G, Decensi A, Formelli F, Chiesa F, Nava M, Camerini T, Marubini E, Veronesi U. Costa A, et al. Among authors: decensi a. Ann N Y Acad Sci. 1995 Sep 30;768:148-62. doi: 10.1111/j.1749-6632.1995.tb12118.x. Ann N Y Acad Sci. 1995. PMID: 8526344 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

273 results

Search Page

Filters